GSK (LON:GSK) Hits New 1-Year High – Still a Buy?

Shares of GSK plc (LON:GSK) hit a new 52-week high on Tuesday . The company traded as high as GBX 1,826 and last traded at GBX 1,824.50, with a volume of 4607887 shares traded. The stock had previously closed at GBX 1,772.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Jefferies Financial Group lifted their price target on GSK from GBX 2,000 to GBX 2,100 and gave the stock a “buy” rating in a research report on Monday, November 3rd. Berenberg Bank reiterated a “hold” rating and set a GBX 1,600 price target on shares of GSK in a report on Friday, July 18th. Shore Capital restated a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a report on Monday, October 20th. JPMorgan Chase & Co. upped their price objective on GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,450 price target on shares of GSK in a report on Thursday, July 31st. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of GBX 1,750.

GSK Trading Up 3.0%

The stock has a 50 day moving average of GBX 1,597.26 and a 200-day moving average of GBX 1,488.36. The company has a market capitalization of £73.33 billion, a P/E ratio of 13.72, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts predict that GSK plc will post 175.980975 EPS for the current year.

Insider Activity

In other GSK news, insider Wendy Becker bought 526 shares of the firm’s stock in a transaction dated Friday, September 19th. The shares were purchased at an average cost of GBX 1,503 per share, for a total transaction of £7,905.78. Over the last 90 days, insiders purchased 558 shares of company stock worth $840,455. 0.20% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.